Abemaciclib + Endocrine therapy

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Brain Metastases

Conditions

Brain Metastases, HR+ Metastatic Breast Cancer

Trial Timeline

Nov 30, 2021 → Dec 1, 2026

NCT ID

NCT04923542

About Abemaciclib + Endocrine therapy

Abemaciclib + Endocrine therapy is a phase 1/2 stage product being developed by Eli Lilly for Brain Metastases. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04923542. Target conditions include Brain Metastases, HR+ Metastatic Breast Cancer.

What happened to similar drugs?

5 of 18 similar drugs in Brain Metastases were approved

Approved (5) Terminated (2) Active (13)

✅ExenatideAstraZenecaApproved

✅RivastigmineNovartisApproved

✅Genotropin (PN-180,307) SomatropinPfizerApproved

✅Genotropin + PlaceboPfizerApproved

✅Dotarem® + Gadovist®/Gadavist®GuerbetApproved

🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04923542	Phase 1/2	Recruiting	Nov 30, 2021	Dec 1, 2026	Brain Metastases

Competing Products

20 competing products in Brain Metastases

See all competitors

Product	Company	Stage	Hype Score
Duloxetine + Sugar pill	Eli Lilly	Phase 2	27
Neurosteroid enantiomer	Oragenics	Phase 2	32
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	27
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	29
Eribulin Mesylate	Eisai	Phase 1	29
Pembrolizumab + Lenvatinib	Eisai	Phase 2	42
Palonosetron (Aloxi) and Dexamethasone	Eisai	Phase 2	27
GLIADEL	Eisai	Phase 2	35
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim	Eli Lilly	Phase 1	29
abemaciclib + abemaciclib	Eli Lilly	Phase 2	39
JNJ-17299425	Johnson & Johnson	Phase 2	27
ABT-888	AbbVie	Phase 1	29
Veliparib + Placebo	AbbVie	Phase 2	35
Iressa (Gefitinib)	AstraZeneca	Phase 2	27
Trastuzumab deruxtecan	AstraZeneca	Phase 2	42
Exenatide	AstraZeneca	Approved	43
AZD5213	AstraZeneca	Phase 1	29
Vorinostat	Merck	Phase 1	29